This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Correa, P. Articles by Ruiz, B. Search for Related Content PubMed PubMed Citation Articles by Correa, P. Articles by Ruiz, B.

Gastric Precancerous Process in a High Risk Population: Cohort Follow-up¹

Department of Pathology, Louisiana State University Medical Center, New Orleans, Louisiana 70112 [P. C., D. Z., E. F., B. R.]; School of Public Health, University of Illinois at Chicago, Chicago, Illinois [W. H.]; Department of Pathology, University of Valle Medical School, Cali, Colombia [C. C., T. C.]; Hospital Departmental, Pasto, Colombia [G. Z.]; and Massachusetts Institute of Technology, Cambridge, Massachusetts [S. T.]

In an attempt to characterize the natural history of the gastric precancerous process, 1422 residents of a high risk area of Nariño, Colombia, have been followed from 3–16 years (average 5.1) with repeated gastric biopsies, for a total of 7290 person-years. The original cohort consisted of 1788 individuals yielding a successful completion rate of 79.5%. Comparison of initial and subsequent biopsies revealed a very complex dynamic flow of both progressive and regressive events, suggesting sporadic environmental forces of modulation. One-time measurement of gastric juice, pH, and nitrite failed to predict future events in the gastric mucosa. The net loss of individuals whose gastric mucosa initially showed normal histology or superficial gastritis was 3.3%/year, representing a net gain of 1.7% for chronic atrophic gastritis, 0.9% for intestinal metaplasia, and 0.7% for dysplasia. The incidence rate of gastric cancer in this population was 0.16/100 person-years. The net rates of progression were higher and those of regression lower in older compared to younger individuals. The general pattern detected is that of a slow forward movement in the previously described hierarchical organization of precursor lesions. The presence of progressive as well as regressive changes and the slow pace of change offer special opportunities to inhibit progression through intervention strategies targeting previously identified etiological factors. The difficulties and opportunities offered by the long term follow-up studies as well as the congruency of the findings with current etiological hypotheses are discussed.

¹ Work supported by Grant P01-CA28842 from the National Cancer Institute.

² To whom requests for reprints should be addressed, at Department of Pathology, Louisiana State University Medical Center, 1901 Perdido St., New Orleans, LA 701121393.

Received 11/ 7/89. Revised 3/ 6/90.

This article has been cited by other articles:

				J. Zabaleta, L. J. Su, H.-Y. Lin, R. A. Sierra, M. C. Hall, A. O. Sartor, P. E. Clark, J. J. Hu, and A. C. Ochoa Cytokine genetic polymorphisms and prostate cancer aggressiveness Carcinogenesis, August 1, 2009; 30(8): 1358 - 1362. [Abstract] [Full Text] [PDF]

				L. Fuccio, R. M. Zagari, L. H. Eusebi, L. Laterza, V. Cennamo, L. Ceroni, D. Grilli, and F. Bazzoli Meta-analysis: Can Helicobacter pylori Eradication Treatment Reduce the Risk for Gastric Cancer? Ann Intern Med, July 21, 2009; 151(2): 121 - 128. [Abstract] [Full Text] [PDF]

				R. M. Peek Jr Review: Prevention of gastric cancer: When is treatment of Helicobacter pylori warranted? Therapeutic Advances in Gastroenterology, July 1, 2008; 1(1): 19 - 31. [Abstract] [PDF]

				J. M. Yeh, K. M. Kuntz, M. Ezzati, C. Hur, C. Y. Kong, and S. J. Goldie Development of an Empirically Calibrated Model of Gastric Cancer in Two High-Risk Countries Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1179 - 1187. [Abstract] [Full Text] [PDF]

				M. Plummer, J. Vivas, G. Lopez, J. C. Bravo, S. Peraza, E. Carillo, E. Cano, D. Castro, O. Andrade, V. Sanchez, et al. Chemoprevention of Precancerous Gastric Lesions With Antioxidant Vitamin Supplementation: A Randomized Trial in a High-Risk Population J Natl Cancer Inst, January 17, 2007; 99(2): 137 - 146. [Abstract] [Full Text] [PDF]

				R Mera, E T H Fontham, L E Bravo, J C Bravo, M B Piazuelo, M C Camargo, and P Correa Long term follow up of patients treated for Helicobacter pylori infection Gut, November 1, 2005; 54(11): 1536 - 1540. [Abstract] [Full Text] [PDF]

				C. Ley, A. Mohar, J. Guarner, R. Herrera-Goepfert, L. S. Figueroa, D. Halperin, I. Johnstone, and J. Parsonnet Helicobacter pylori Eradication and Gastric Preneoplastic Conditions: A Randomized, Double-Blind, Placebo-Controlled Trial Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 4 - 10. [Abstract] [Full Text] [PDF]

				P. Correa Chemoprevention of Gastric Cancer: Has the Time Come? J. Clin. Oncol., December 1, 2003; 21(90230): 270s - 271. [Full Text] [PDF]

				P. Correa Bacterial Infections as a Cause of Cancer J Natl Cancer Inst, April 2, 2003; 95(7): E3 - E3. [Full Text]

				Risk factors for atrophic chronic gastritis in a European population: results of the Eurohepygast study Gut, June 1, 2002; 50(6): 779 - 785. [Abstract] [Full Text] [PDF]

				M F DIXON Prospects for intervention in gastric carcinogenesis: reversibility of gastric atrophy and intestinal metaplasia Gut, July 1, 2001; 49(1): 2 - 4. [Full Text] [PDF]

				C. Imrie, M. Rowland, B. Bourke, and B. Drumm Is Helicobacter pylori Infection in Childhood a Risk Factor for Gastric Cancer? Pediatrics, February 1, 2001; 107(2): 373 - 380. [Abstract] [Full Text]

				N C T van Grieken, M M Weiss, G A Meijer, E Bloemena, J Lindeman, G J A Offerhaus, S G M Meuwissen, J P A Baak, and E J Kuipers Rapid quantitative assessment of gastric corpus atrophy in tissue sections J. Clin. Pathol., January 1, 2001; 54(1): 63 - 69. [Abstract] [Full Text] [PDF]

				P. Correa, E. T. H. Fontham, J. C. Bravo, L. E. Bravo, B. Ruiz, G. Zarama, J. L. Realpe, G. T. Malcom, D. Li, W. D. Johnson, et al. Chemoprevention of Gastric Dysplasia: Randomized Trial of Antioxidant Supplements and Anti-Helicobacter pylori Therapy J Natl Cancer Inst, December 6, 2000; 92(23): 1881 - 1888. [Abstract] [Full Text] [PDF]

				A. K. Walch, H. F. Zitzelsberger, J. Bruch, G. Keller, D. Angermeier, M. M. Aubele, J. Mueller, H. Stein, H. Braselmann, J. R. Siewert, et al. Chromosomal Imbalances in Barrett’s Adenocarcinoma and the Metaplasia-Dysplasia-Carcinoma Sequence Am. J. Pathol., February 1, 2000; 156(2): 555 - 566. [Abstract] [Full Text] [PDF]

				C. Gong, R. Mera, J. C. Bravo, B. Ruiz, R. Diaz-Escamilla, E. T. H. Fontham, P. Correa, and J. D. Hunt KRAS Mutations Predict Progression of Preneoplastic Gastric Lesions Cancer Epidemiol. Biomarkers Prev., February 1, 1999; 8(2): 167 - 171. [Abstract] [Full Text]

				A. Kokkola, H. Rautelin, P. Puolakkainen, P. Sipponen, M. Färkkilä, R. Haapiainen, and T. U. Kosunen Positive Result by Serology Indicates Active Helicobacter pylori Infection in Patients with Atrophic Gastritis J. Clin. Microbiol., June 1, 1998; 36(6): 1808 - 1810. [Abstract] [Full Text]

				E. J. Kuipers, L. Lundell, E. C. Klinkenberg-Knol, N. Havu, H. P.M. Festen, B. Liedman, C. B.H.W. Lamers, J. B.M.J. Jansen, J. Dalenback, P. Snel, et al. Atrophic Gastritis and Helicobacter pylori Infection in Patients with Reflux Esophagitis Treated with Omeprazole or Fundoplication N. Engl. J. Med., April 18, 1996; 334(16): 1018 - 1022. [Abstract] [Full Text] [PDF]

				S. A. Hundahl, G. N. Stemmermann, and A. Oishi Racial Factors Cannot Explain Superior Japanese Outcomes in Stomach Cancer Arch Surg, February 1, 1996; 131(2): 170 - 175. [Abstract] [PDF]